Overview

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Status:
Completed

Trial end date:
2019-10-23

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Dolutegravir
Emtricitabine
Emtricitabine tenofovir alafenamide
Lamivudine
Tenofovir
Triumeq